AnalystBook Research · Company Intelligence

Tyra Biosciences, Inc.

TYRANasdaq

Built from Tyra Biosciences, Inc.'s own SEC filings · updates as new filings land · sources cited throughout

or browse all covered companies

The read at a glance

Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.

  • Distress risk · Altman Z-Score 9.92 safe zoneOK

Leadership changes

From Tyra Biosciences, Inc.'s own filings, the day they're filed.

  • Bhavesh Ashar · Chief Operating Officer · appointmenteff. 2025-12-01
  • Daniel Bensen · Chief Commercial Officer · appointmenteff. 2025-12-01
  • Nina Kjellson · director · departureeff. 2025-01-29

Latest filings

  • 10-Q · Quarterly report2026-08-04
  • 8-K · Company announcement2026-08-04
  • 8-K · Company announcement2026-06-02
  • 8-K · Company announcement2026-05-13
  • 10-Q · Quarterly report2026-05-13
In the full recordFree for 14 days
  • The filings, readable — with what changed vs the prior year highlighted🔒
  • Full financial statements, industry-aware, sources cited throughout🔒
  • Forensic score history & components — the trend, not one year🔒
  • Ownership: insider buys/sells, clusters, activist stakes🔒
  • Ana — ask about Tyra Biosciences, Inc., every answer cited to the official filings🔒
  • The Intelligence Brief — added when Tyra Biosciences, Inc.'s brief passes our SEC-figure check🔒

Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.

14-day free trial, no credit card. For research purposes only; not investment advice.